NASDAQ:NERV Minerva Neurosciences - NERV Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.36 +0.15 (+6.79%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.21▼$2.4450-Day Range$1.43▼$3.5952-Week Range$1.26▼$15.27Volume48,349 shsAverage Volume147,379 shsMarket Capitalization$12.60 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Minerva Neurosciences MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside239.0% Upside$8.00 Price TargetShort InterestHealthy3.83% of Float Sold ShortDividend StrengthN/ASustainability-0.89Upright™ Environmental ScoreNews Sentiment0.29Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.10) to ($2.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 starsMedical Sector579th out of 1,054 stocksPharmaceutical Preparations Industry292nd out of 517 stocks 3.0 Analyst's Opinion Consensus RatingMinerva Neurosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Minerva Neurosciences has a forecasted upside of 239.0% from its current price of $2.36.Amount of Analyst CoverageMinerva Neurosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.83% of the float of Minerva Neurosciences has been sold short.Short Interest Ratio / Days to CoverMinerva Neurosciences has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Minerva Neurosciences has recently increased by 20.15%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMinerva Neurosciences does not currently pay a dividend.Dividend GrowthMinerva Neurosciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMinerva Neurosciences has received a 71.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for Parkinsonism", "Clinical research services for schizophrenia", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Minerva Neurosciences is -0.89. Previous Next 2.9 News and Social Media Coverage News SentimentMinerva Neurosciences has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Minerva Neurosciences this week, compared to 1 article on an average week.Search Interest3 people have searched for NERV on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows5 people have added Minerva Neurosciences to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Minerva Neurosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Minerva Neurosciences is held by insiders.Percentage Held by InstitutionsOnly 38.00% of the stock of Minerva Neurosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Minerva Neurosciences are expected to grow in the coming year, from ($6.10) to ($2.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Minerva Neurosciences is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Minerva Neurosciences is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMinerva Neurosciences has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Minerva Neurosciences (NASDAQ:NERV) StockMinerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson's disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Waltham, MA.Read More Receive NERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NERV Stock News HeadlinesJanuary 25, 2023 | americanbankingnews.comMinerva Neurosciences (NASDAQ:NERV) Upgraded to Hold at StockNews.comDecember 29, 2022 | marketwatch.comStocks to Watch: Cal-Maine Foods, Hyzon Motors, Minerva NeurosciencesJanuary 29, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 28, 2022 | markets.businessinsider.comTesla, Amazon, Minerva, Kala Pharma, Gorilla Tech: Why These 5 Stocks Are Drawing Investors' Attention TodayDecember 28, 2022 | marketwatch.comMinerva Neurosciences Shares Decline 39% on FDA Application Refusal for RoluperidoneDecember 28, 2022 | marketwatch.comMinerva Neurosciences Says FDA Rejected Application for Schizophrenia DrugDecember 28, 2022 | finance.yahoo.comMinerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in SchizophreniaNovember 10, 2022 | finanznachrichten.deMinerva Neurosciences, Inc: Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business UpdatesJanuary 29, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 9, 2022 | seekingalpha.comMinerva Neurosciences, Inc. (NERV) Q3 2022 Earnings Call TranscriptNovember 9, 2022 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: GlycoMimetics (GLYC) and Minerva Neurosciences (NERV)November 9, 2022 | finance.yahoo.comMinerva Neurosciences Reports Third Quarter 2022 Financial Results and Business UpdatesNovember 2, 2022 | finance.yahoo.comMinerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022October 17, 2022 | nasdaq.comMinerva Neurosciences: FDA Refuses To Accept NDA For RoluperidoneOctober 17, 2022 | marketwatch.comMinerva Neurosciences Shares Drop 58% After FDA Refusal to File LetterOctober 17, 2022 | msn.comLooking Into Minerva Neurosciences's Recent Short InterestOctober 17, 2022 | finance.yahoo.comMinerva Neurosciences Shares Sink On Regulatory Setback For Schizophrenia CandidateOctober 17, 2022 | marketwatch.comMinerva Neurosciences Gets Refusal to File Letter From FDA for RoluperidoneOctober 17, 2022 | finance.yahoo.comMinerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in SchizophreniaOctober 17, 2022 | finance.yahoo.comMinerva Neurosciencs to request meeting with FDA about schizophrenia drugSeptember 28, 2022 | msn.comHow Is The Market Feeling About Minerva Neurosciences?September 28, 2022 | finance.yahoo.comMinerva University Launches Graduate Certificate in Decision Analysis and Graduate Immersion OpportunitiesSeptember 26, 2022 | 247wallst.comLeading Indicators Say Minerva Neuro Could Be Ripe For Another Short SqueezeSeptember 26, 2022 | markets.businessinsider.com10 Short Squeeze Candidates That May Soar: Minerva Neurosciences, FaZe, Getty Images And MoreSeptember 9, 2022 | finanznachrichten.deMinerva Neurosciences, Inc: Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital MarketSeptember 9, 2022 | finance.yahoo.comMinerva Neurosciences Announces Listing Transfer to Nasdaq Capital MarketAugust 25, 2022 | seekingalpha.comMinerva Neurosciences rises 42% after Steven Cohen firm discloses large stakeSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NERV Company Calendar Last Earnings11/09/2022Today1/29/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NERV CUSIPN/A CIK1598646 Webwww.minervaneurosciences.com Phone(617) 600-7373FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+239.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($8.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,910,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-485.51% Return on Assets-44.62% Debt Debt-to-Equity RatioN/A Current Ratio20.41 Quick Ratio20.41 Sales & Book Value Annual Sales$41.18 million Price / Sales0.31 Cash FlowN/A Price / Cash FlowN/A Book Value$1.49 per share Price / Book1.58Miscellaneous Outstanding Shares5,340,000Free Float5,046,000Market Cap$12.60 million OptionableOptionable Beta-0.04 Key ExecutivesRémy Henri LuthringerExecutive Chairman & Chief Executive OfficerGeoff RacePresidentJoseph ReillyChief Operating Officer & Senior Vice PresidentFred AhlholmChief Financial Officer, Secretary & Senior VPMichael DavidsonChief Medical OfficerKey CompetitorsContext TherapeuticsNASDAQ:CNTXBellicum PharmaceuticalsNASDAQ:BLCMCingulateNASDAQ:CINGVascular BiogenicsNASDAQ:VBLTLixte BiotechnologyNASDAQ:LIXTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 328,483 shares on 11/15/2022Ownership: 3.064%BlackRock Inc.Bought 27,612 shares on 11/15/2022Ownership: 1.462%Renaissance Technologies LLCBought 66,189 shares on 11/14/2022Ownership: 1.906%Point72 Asset Management L.P.Bought 25,000 shares on 11/14/2022Ownership: 0.468%UBS Group AGBought 5,167 shares on 11/10/2022Ownership: 0.107%View All Institutional Transactions NERV Stock - Frequently Asked Questions Should I buy or sell Minerva Neurosciences stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NERV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NERV, but not buy additional shares or sell existing shares. View NERV analyst ratings or view top-rated stocks. What is Minerva Neurosciences' stock price forecast for 2023? 2 Wall Street analysts have issued 1 year price targets for Minerva Neurosciences' shares. Their NERV share price forecasts range from $8.00 to $8.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 239.0% from the stock's current price. View analysts price targets for NERV or view top-rated stocks among Wall Street analysts. How have NERV shares performed in 2023? Minerva Neurosciences' stock was trading at $1.59 at the beginning of the year. Since then, NERV stock has increased by 48.4% and is now trading at $2.36. View the best growth stocks for 2023 here. Are investors shorting Minerva Neurosciences? Minerva Neurosciences saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 174,100 shares, an increase of 20.2% from the December 31st total of 144,900 shares. Based on an average trading volume of 169,500 shares, the days-to-cover ratio is currently 1.0 days. Approximately 3.8% of the company's shares are sold short. View Minerva Neurosciences' Short Interest. When is Minerva Neurosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our NERV earnings forecast. How were Minerva Neurosciences' earnings last quarter? Minerva Neurosciences, Inc. (NASDAQ:NERV) announced its quarterly earnings data on Wednesday, November, 9th. The biopharmaceutical company reported ($1.29) EPS for the quarter, beating analysts' consensus estimates of ($1.46) by $0.17. When did Minerva Neurosciences' stock split? Minerva Neurosciences shares reverse split before market open on Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What other stocks do shareholders of Minerva Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD). What is Minerva Neurosciences' stock symbol? Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV." How do I buy shares of Minerva Neurosciences? Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Minerva Neurosciences' stock price today? One share of NERV stock can currently be purchased for approximately $2.36. How much money does Minerva Neurosciences make? Minerva Neurosciences (NASDAQ:NERV) has a market capitalization of $12.60 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $-49,910,000.00 in net income (profit) each year or ($8.76) on an earnings per share basis. How can I contact Minerva Neurosciences? Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The official website for the company is www.minervaneurosciences.com. The biopharmaceutical company can be reached via phone at (617) 600-7373 or via email at wboni@minervaneurosciences.com. This page (NASDAQ:NERV) was last updated on 1/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.